Effect of excessive gestational weight on daughters’ breast density at the end of puberty onset
Author
dc.contributor.author
López, Ana
Author
dc.contributor.author
Garmendia Miguel, María Luisa
Author
dc.contributor.author
Shepherd, John
Author
dc.contributor.author
Michels, Karin
Author
dc.contributor.author
Corvalán Aguilar, Camila
Author
dc.contributor.author
Pereira Scalabrino, Ana
Admission date
dc.date.accessioned
2020-06-23T22:02:53Z
Available date
dc.date.available
2020-06-23T22:02:53Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Scientific Reports | (2020) 10:6636
es_ES
Identifier
dc.identifier.other
10.1038/s41598-020-63260-9
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/175657
Abstract
dc.description.abstract
The effect of excessive gestational weight gain (EGWG) is related to adverse health outcomes in the offspring; however, its effect on the daughters' breast density is unclear. We aimed to assess the association between EGWG and daughters' breast composition (% of fibroglandular volume (%FGV) and absolute fibroglandular volume (AFGV)) at Tanner stage 4 (Tanner B4)). We included 341 girls and their mothers from an ongoing cohort of low-income Chilean girls born from 2002-2003. Maternal gestational weight gain was self-reported in 2007, and breast density by digital mammography was measured in 2010. Weight, height and breast composition by dual X-ray absorptiometry (DXA) were measured in daughters at Tanner B4. Logistic regression models were run to assess the association between EGWG and the 80th percentile of %FGV and AFGV. Mean gestational weight gain was 13.7kg (SD=6.9kg). Women with pregestational overweight or obesity exceeded the recommended gestational weight gain (58.8% vs. 31.8%, respectively). Daughters of women who had EGWG had higher levels of AFGV (OR: 2.02; 95%CI 1.16-3.53) at Tanner B4, which could be explained by metabolic and hormonal exposure in utero. However, we did not observe an association with %FGV.
es_ES
Patrocinador
dc.description.sponsorship
Chilean Council for Science and Technology
FONDECYT 11170670
World Cancer Research Fund International (WCRF)
2010/245
United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
NIH National Cancer Institute (NCI)
5R01CA158313
PCI Proyecto
REDI170060